Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer

Ananaya Datta-Mitra, Navdeep K. Riar, Siba P Raychaudhuri

Research output: Contribution to journalArticle

15 Scopus citations


Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.

Original languageEnglish (US)
Pages (from-to)632
Number of pages1
JournalIndian Journal of Dermatology
Issue number6
StatePublished - Nov 1 2014



  • Angiogenesis
  • bevacizumab
  • psoriatic arthritis

ASJC Scopus subject areas

  • Dermatology

Cite this